查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088845

被忽視的熱帶疾病治療市場：2026-2032年全球市場預測（按藥物類型、給藥途徑、治療方法、適應症、患者年齡層和最終用戶分類）

Neglected Tropical Disease Treatment Market by Drug Type, Route Of Administration, Treatment Approach, Disease Indication, Patient Age group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，被忽視的熱帶疾病治療市場將成長至 63.4 億美元，複合年成長率為 5.92%。

主要市場統計數據
基準年 2025 42.4億美元
預計年份：2026年 44.7億美元
預測年份 2032 63.4億美元
複合年成長率 (%) 5.92%

被忽視的熱帶疾病（NTD）的治療正從主導捐贈的大規模藥物治療轉向以數據為導向的綜合疾病控制方法，該方法結合了藥物治療、診斷、病媒控制、監測和社區服務。這個治療願景源自於世界衛生組織（世衛組織）的2021-2030年藍圖，藍圖路線圖旨在將需要NTD控制的人數減少90%，並在100個國家根除至少一種被忽視的熱帶疾病。

全球有超過十億人受到被忽視的熱帶疾病（NTD）的影響，資源匱乏的熱帶和亞熱帶地區負擔尤其沉重，因此需求仍然旺盛。成長機會主要集中在擴充性的抗寄生蟲療法、即時診斷、兒童製劑、支持用藥依從性的數位化工具，以及將公共衛生成果與永續取得模式相結合的夥伴關係。

被忽視的熱帶疾病治療前景的變革性變化

長期以來被忽視的熱帶疾病（NTD）治療領域正透過綜合疾病控制計畫、加強藥物監測系統以及從以宣傳活動為基礎的干預措施轉向持續監測進行重組。各國正日益將淋巴絲蟲病、盤尾絲蟲病、土源性蠕蟲病、利什曼原蟲症、沙眼、南美錐蟲病、利甚曼病和登革熱的防治措施納入基層醫療和社區衛生保健系統。

人工智慧對被忽視的熱帶疾病治療的累積影響

人工智慧透過改進風險評估、診斷、臨床試驗設計和藥物分發，正在整體被忽視的熱帶疾病（NTDs）的治療創造累積價值。利用氣候、人口遷移、病媒和病例報告數據的機器學習模型，有助於識別登革熱、血吸蟲病、利什曼原蟲症和其他疾病的感染集中區域，這些區域的感染模式會隨著降雨、溫度、都市化和人口流動而變化。

NTD治療市場的關鍵區域洞察

亞太地區在被忽視的熱帶疾病（NTD）防治方面繼續發揮核心作用，這得益於其龐大的高風險人口、強力的公共衛生宣傳活動，以及某些地區持續存在的登革熱、土源性蠕蟲病、淋巴絲蟲病、血吸蟲病和麻風病等疾病負擔。該地區受益於大規模驅蟲舉措、學校藥物分發和不斷擴大的檢測能力，但島嶼和邊境地區仍需持續監測。北美透過公共衛生專業知識、聯邦研究支援、診斷技術創新和採購影響力做出貢獻，同時也推動輸入性病例的管理，並應對溫帶地區日益成長的媒介傳播疾病風險。

關於NTD治療策略的關鍵小組研究結果

東南亞國協正透過登革熱預防計畫、驅蟲宣傳活動、淋巴絲蟲病根除和跨國監測等措施推進被忽視的熱帶疾病（NTD）防治工作。該區域集團在社區大規模醫療服務和病媒控制創新方面發揮著至關重要的作用。雖然海灣合作理事會（GCC）國家不像熱帶地區那樣承受著地方性NTD的沉重負擔，但它們在旅行者健康、移民健康篩檢、人道主義援助資金以及登革熱和利什曼原蟲症監測方面正發揮著日益重要的作用，尤其是在人口流動、都市化和氣候適應導致區域風險模式發生變化的情況下。

主要國家的發展趨勢正在影響對被忽視的熱帶疾病治療的需求。

美國在資助被忽視的熱帶疾病研究、制定公共衛生指南和診斷方法以及藥物研發夥伴關係方面發揮著主導作用，而加拿大則透過資助全球衛生、監測專業知識和學術熱帶醫學計畫做出貢獻。墨西哥和巴西仍然是拉丁美洲的重要市場，因為它們在登革熱、南美錐蟲病、利什曼原蟲症和病媒控制方面具有優先地位，而且巴西在蟲媒病毒感染疾病的管理和公共部門提供治療方面也擁有豐富的經驗。英國、德國和法國在臨床研究、捐助資金、監管科學、藥物安全監測以及官民合作關係促進藥物取得方面具有影響力。

為行業領導者提供的實用建議

產業領導者應優先考慮價格合理的配方、耐熱產品、兒童劑量以及適合當地醫療體系的簡化給藥方法。與衛生署、世界衛生組織指南計畫、非政府組織、學術機構和當地生產商夥伴關係，可以改善藥品可及性，同時有助於創造永續的需求並獲得監管部門的批准。

調查方法

本執行摘要採用系統的二手研究方法編寫，數據來自世界衛生組織（世衛組織）、各國公共衛生機構、同行評審文獻、臨床研究途徑註冊庫、監管資訊來源以及經認可的全球衛生組織的公開數據。其解讀與世衛組織被忽視的熱帶疾病路線藍圖優先事項、疾病負擔模式、治療指南、藥品捐贈框架和採購趨勢一致。

結論

被忽視的熱帶疾病（NTD）的治療正進入一個更全面和技術驅動的階段。根除目標、人工智慧驅動的監測、改進的診斷技術以及可靠的藥物取得途徑正在塑造著戰略方向。該領域仍然面臨著許多未被滿足的需求、公共衛生形勢的緊迫性以及對價格合理且即使在資源匱乏的環境中也能可靠發揮作用的產品的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：被忽視的熱帶疾病治療市場：依藥物類型分類

  • 藥物治療
    • 抗寄生蟲藥物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
  • 生物製藥和免疫療法
    • 治療性疫苗
    • 單株抗體
  • 外科手術和介入治療

第8章：被忽視的熱帶疾病治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用

第9章：被忽視的熱帶疾病治療市場：依治療方法分類

  • 團體用藥
  • 標靶治療

第10章：被忽視的熱帶疾病治療市場：依疾病適應症分類

  • 病毒性被忽視的熱帶疾病
    • 登革熱
    • 基孔古尼亞
    • 狂犬病
  • 細菌性神經管缺陷
    • 布里氏潰瘍
    • 沙眼
    • 亞斯
  • 寄生蟲引起的被忽視的熱帶疾病
    • 原蟲性疾病
    • 蠕蟲感染疾病
  • 真菌性神經管缺陷

第11章：被忽視的熱帶疾病治療市場：依患者年齡層分類

  • 兒童
  • 成人
  • 老年人

第12章：被忽視的熱帶疾病治療市場：依最終用戶分類

  • 診所
  • 社區健康中心
  • 醫院
  • 研究機構和臨床試驗設施

第13章：被忽視的熱帶疾病治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：被忽視的熱帶疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 被忽視的熱帶疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Eiken Chemical Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS SA
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sinopharm Group Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-AD36CD897E7F

The Neglected Tropical Disease Treatment Market is projected to grow by USD 6.34 billion at a CAGR of 5.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.24 billion
Estimated Year [2026] USD 4.47 billion
Forecast Year [2032] USD 6.34 billion
CAGR (%) 5.92%

Neglected tropical disease treatment is moving from donation-led mass drug administration toward integrated, data-driven disease control that combines medicines, diagnostics, vector management, surveillance, and community delivery. The treatment landscape is shaped by the World Health Organization road map for 2021-2030, which targets a 90% reduction in people requiring NTD interventions and the elimination of at least one neglected tropical disease in 100 countries.

Demand remains significant because more than 1 billion people are affected by NTDs, with the highest burden in low-resource tropical and subtropical settings. Growth opportunities are concentrated in scalable antiparasitic therapies, point-of-care diagnostics, pediatric formulations, digital adherence tools, and partnerships that align public health outcomes with sustainable access models.

Transformative Shifts in the NTD Treatment Landscape

The neglected tropical disease treatment landscape is being reshaped by integrated disease programs, stronger pharmacovigilance, and a shift from campaign-based interventions to continuous surveillance. Countries are increasingly combining lymphatic filariasis, onchocerciasis, soil-transmitted helminthiasis, schistosomiasis, trachoma, Chagas disease, leishmaniasis, and dengue strategies with primary care and community health systems.

Transformative momentum is also coming from fixed-dose combinations, shorter treatment regimens, vector-control innovation, and expanded regulatory pathways for priority medicines. Donor-funded access remains vital, but procurement decisions are becoming more evidence based, with ministries and global health agencies prioritizing treatments that demonstrate safety, operational simplicity, resistance monitoring, and measurable progress toward elimination targets.

Cumulative Impact of Artificial Intelligence on NTD Treatment

Artificial intelligence is creating cumulative value across neglected tropical disease treatment by improving risk mapping, diagnosis, trial design, and medicine distribution. Machine learning models using climate, mobility, vector, and case-reporting data can help identify hotspots for dengue, schistosomiasis, leishmaniasis, and other diseases where transmission changes with rainfall, temperature, urbanization, and population movement.

AI-enabled image analysis is strengthening microscopy, lesion recognition, and field diagnostics, while predictive analytics can reduce stockouts during mass drug administration campaigns. The highest-impact use cases are those validated in local health systems, governed by transparent data standards, and paired with human expertise to avoid bias in underserved populations.

Key Regional Insights Across NTD Treatment Markets

Asia-Pacific remains central to NTD treatment because of large at-risk populations, strong public health campaigns, and continuing burdens from dengue, soil-transmitted helminths, lymphatic filariasis, schistosomiasis, and leprosy in selected settings. The region benefits from large-scale deworming initiatives, school-based delivery, and expanding laboratory capacity, while island and border areas continue to require sustained surveillance. North America contributes through public health expertise, federally supported research, diagnostics innovation, and procurement influence, while also managing imported cases and rising vector-borne disease risk in warmer regions.

Latin America is a priority region for Chagas disease, leishmaniasis, dengue, and soil-transmitted helminth control, with established vector-control programs and national surveillance systems supporting treatment access. Europe is important for funding, regulatory science, tropical medicine research, and management of travel-associated and migration-linked infections. The Middle East faces risk from cutaneous leishmaniasis, dengue emergence, and population mobility, making surveillance and migrant health services increasingly relevant. Africa carries the largest NTD burden and remains the core region for mass drug administration, elimination programs, community-directed treatment, and integrated control of lymphatic filariasis, onchocerciasis, schistosomiasis, trachoma, and soil-transmitted helminthiasis.

Key Group Insights for NTD Treatment Strategy

ASEAN countries are advancing NTD control through dengue programs, deworming campaigns, lymphatic filariasis elimination, and cross-border surveillance, making the bloc important for scalable community delivery and vector-control innovation. GCC countries are less burdened by endemic NTDs than tropical regions but play a growing role in travel health, migrant health screening, humanitarian financing, and surveillance for dengue and leishmaniasis, particularly as mobility, urbanization, and climate suitability shift regional risk patterns.

The European Union supports neglected tropical disease treatment through health research funding, regulatory harmonization, and global health programs that strengthen diagnostics, medicines development, and implementation science. BRICS countries combine high disease burden, manufacturing scale, and expanding clinical research capacity, particularly across Brazil, India, China, and South Africa. G7 members remain pivotal funders of research, procurement, and access initiatives, while NATO countries indirectly influence preparedness through humanitarian logistics, biosecurity cooperation, emergency response planning, and health-system resilience relevant to outbreak-prone and climate-sensitive NTDs.

Key Country Insights Shaping NTD Treatment Demand

The United States leads in NTD research funding, public health guidance, diagnostics development, and drug discovery partnerships, while Canada contributes through global health financing, surveillance expertise, and academic tropical medicine programs. Mexico and Brazil remain essential Latin American markets because of dengue, Chagas disease, leishmaniasis, and vector-control priorities, with Brazil also holding significant expertise in arboviral disease management and public-sector treatment delivery. The United Kingdom, Germany, and France are influential in clinical research, donor funding, regulatory science, pharmacovigilance, and public-private partnerships for access.

Russia, Italy, and Spain are relevant for surveillance, travel medicine, and imported or climate-sensitive vector-borne disease risk, particularly as Aedes mosquito distribution and heat-related transmission suitability change across parts of Europe. China has made major progress against schistosomiasis and has broad pharmaceutical manufacturing and diagnostics capacity. India carries one of the largest NTD treatment needs, especially for lymphatic filariasis, visceral leishmaniasis, soil-transmitted helminths, leprosy, and dengue, supported by national elimination programs and large-scale community health infrastructure. Japan, Australia, and South Korea add value through innovation, regional health security, diagnostics, development assistance, and Indo-Pacific surveillance partnerships.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize affordable formulations, heat-stable products, pediatric dosing, and simplified regimens that fit community health delivery. Partnerships with ministries of health, WHO-aligned programs, NGOs, academic centers, and local manufacturers can improve access while supporting sustainable demand generation and regulatory acceptance.

Organizations should also invest in field-ready diagnostics, AI-supported surveillance, pharmacovigilance, and evidence packages that demonstrate cost-effectiveness, safety, adherence, and impact on elimination goals. The strongest competitive positions will come from combining product innovation with implementation support, local capacity building, resistance monitoring, supply-chain resilience, and transparent access commitments.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available data from the World Health Organization, national public health agencies, peer-reviewed literature, clinical trial registries, regulatory sources, and recognized global health organizations. Interpretation is aligned with WHO NTD road map priorities, disease-burden patterns, treatment guidelines, medicine donation frameworks, and procurement dynamics.

Insights are triangulated across epidemiology, policy, funding, pipeline activity, regional disease prevalence, access initiatives, and technology adoption indicators. Findings are validated for consistency across sources and framed to support strategic planning, competitive assessment, and opportunity prioritization in neglected tropical disease treatment without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Neglected tropical disease treatment is entering a more integrated and technology-enabled phase, with elimination goals, AI-supported surveillance, improved diagnostics, and resilient medicine access shaping strategic direction. The sector remains defined by high unmet need, public health urgency, and the need for affordable products that perform reliably in low-resource environments.

Organizations that align innovation with community delivery, evidence-based procurement, and regional elimination priorities will be best positioned to create measurable health impact. The long-term opportunity lies in closing access gaps while building sustainable systems for detection, treatment, monitoring, prevention, and equitable care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neglected Tropical Disease Treatment Market, by Drug Type

  • 7.1. Drug therapy
    • 7.1.1. Antiparasitics
    • 7.1.2. Antibacterials
    • 7.1.3. Antivirals
    • 7.1.4. Antifungals
  • 7.2. Biologics & Immunotherapy
    • 7.2.1. Therapeutic Vaccines
    • 7.2.2. Monoclonal Antibodies
  • 7.3. Surgical/Procedural interventions

8. Neglected Tropical Disease Treatment Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Topical

9. Neglected Tropical Disease Treatment Market, by Treatment Approach

  • 9.1. Mass Drug Administration
  • 9.2. Targeted Therapy

10. Neglected Tropical Disease Treatment Market, by Disease Indication

  • 10.1. Viral NTDs
    • 10.1.1. Dengue
    • 10.1.2. Chikungunya
    • 10.1.3. Rabies
  • 10.2. Bacterial NTDs
    • 10.2.1. Buruli Ulcer
    • 10.2.2. Trachoma
    • 10.2.3. Yaws
  • 10.3. Parasitic NTDs
    • 10.3.1. Protozoan Infections
    • 10.3.2. Helminthic Infections
  • 10.4. Fungal NTDs

11. Neglected Tropical Disease Treatment Market, by Patient Age group

  • 11.1. Pediatric
  • 11.2. Adult
  • 11.3. Geriatic

12. Neglected Tropical Disease Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Community Health Centers
  • 12.3. Hospitals
  • 12.4. Research Institutes & Clinical Trial Sites

13. Neglected Tropical Disease Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Neglected Tropical Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neglected Tropical Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Astellas Pharma Inc.
  • 17.3. AstraZeneca plc
  • 17.4. Bayer AG
  • 17.5. Boehringer Ingelheim International GmbH
  • 17.6. Bristol Myers Squibb Company
  • 17.7. Cipla Limited
  • 17.8. Daiichi Sankyo Company, Limited
  • 17.9. Eiken Chemical Co., Ltd.
  • 17.10. Eisai Co., Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. EMS S.A.
  • 17.13. F. Hoffmann-La Roche Ltd
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Johnson & Johnson
  • 17.17. Merck & Co., Inc.
  • 17.18. Merck KGaA
  • 17.19. Novartis AG
  • 17.20. Novo Nordisk A/S
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi S.A.
  • 17.23. Shionogi & Co., Ltd.
  • 17.24. Sinopharm Group Co. Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL NTDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL NTDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL NTDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DENGUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHIKUNGUNYA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHIKUNGUNYA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHIKUNGUNYA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIAL NTDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIAL NTDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIAL NTDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BURULI ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BURULI ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BURULI ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRACHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRACHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRACHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL YAWS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL YAWS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL YAWS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARASITIC NTDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARASITIC NTDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARASITIC NTDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FUNGAL NTDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNGAL NTDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FUNGAL NTDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GERIATIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GERIATIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GERIATIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 216. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 255. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 268. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKE